Latest Articles

Publication Date
All News Scientific
Safety, Pharmacokinetics, and Sex Hormone Suppression of LY01021 versus Relugolix: A Single- and Multiple-Dose Escalation Study.

LY01021 is a novel oral small-molecule gonadotropin-releasing hormone (GnRH) receptor antagonist intended for the treatment of various sex hormone-dependent disorders. This study aimed to evaluate the safety, tolerability, pharmacokinetics (PK), …

Published: Feb. 5, 2026, midnight
Read Full Article
Assisted reproduction Endometriosis GnRH receptor antagonist Prostate cancer Sex hormone
Joondalup Health Campus joins global cancer treatment trial - PerthNow

Joondalup Health Campus joins global cancer treatment trial PerthNow

Published: Feb. 4, 2026, 6 p.m.
Read Full Article
World Cancer Day: 10 ways Northside is fighting cancer - Northside Hospital

World Cancer Day: 10 ways Northside is fighting cancer Northside Hospital

Published: Feb. 4, 2026, 3:13 p.m.
Read Full Article
Inoperable To Cancer-Free: Medanta Doctors Achieve Rare Complete Response In Advanced Endometrial Cancer - BW Healthcare World

Inoperable To Cancer-Free: Medanta Doctors Achieve Rare Complete Response In Advanced Endometrial Cancer BW Healthcare World

Published: Feb. 4, 2026, 7:56 a.m.
Read Full Article
Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer - BioSpace

Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer BioSpace

Published: Feb. 4, 2026, 4:47 a.m.
Read Full Article
Doctors warn of rise in cancers among women - The New Indian Express

Doctors warn of rise in cancers among women The New Indian Express

Published: Feb. 4, 2026, 2:37 a.m.
Read Full Article
Gsk - Quebec To Reimburse Jemperli Plus Chemotherapy Via Ramq For Primary Advanced/First Recurrent Endometrial Cancer - TradingView

Gsk - Quebec To Reimburse Jemperli Plus Chemotherapy Via Ramq For Primary Advanced/First Recurrent Endometrial Cancer TradingView

Published: Feb. 3, 2026, 1:11 p.m.
Read Full Article
Why Endometrial Cancer Is Rising Among Younger Women And What Doctors Want You To Know - News18

Why Endometrial Cancer Is Rising Among Younger Women And What Doctors Want You To Know News18

Published: Feb. 3, 2026, 1:06 p.m.
Read Full Article
Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer - Newswire Canada

Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer Newswire …

Published: Feb. 3, 2026, 1 p.m.
Read Full Article
Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer - Yahoo Finance Singapore

Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer Yahoo …

Published: Feb. 3, 2026, 1 p.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!